Related Experiment Video

Updated: May 3, 2026

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
11:10

Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice

Published on: November 16, 2011

97.6K

The StatStrip glucose monitor is suitable for use during hyperinsulinemic euglycemic clamps in a pediatric population

Kara A Lindquist1, Kelsey Chow, Amy West

  • 11 University of Colorado Denver , Children's Hospital Colorado, Aurora, Colorado.

Diabetes Technology & Therapeutics
|January 30, 2014
PubMed

Insights

The StatStrip glucose meter is a reliable and accurate alternative to the YSI analyzer for pediatric hyperinsulinemic euglycemic clamp studies, offering improved ease of use and cost-effectiveness.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Research
  • Clinical Diagnostics

Background:

  • Hyperinsulinemic euglycemic clamp is the gold standard for insulin resistance assessment.
  • YSI 2300 STAT Plus glucose analyzer is commonly used but has limitations (cost, time, personnel, maintenance, blood volume).
  • Hospital-grade glucose meters lack validation in pediatric clamp settings.

Purpose of the Study:

  • Evaluate the accuracy, precision, and reliability of the StatStrip (SS) glucose monitoring system.
  • Compare SS performance against the YSI 2300 STAT glucose analyzer in pediatric hyperinsulinemic euglycemic clamps.

Main Methods:

  • Simultaneous analysis of 460 blood specimens from 11 pediatric patients.
  • Measured SS bias relative to YSI and glucose measurement precision on both systems.
  • Utilized Bland-Altman analysis for agreement assessment.

Main Results:

  • StatStrip showed a slight positive bias of 0.75 ± 2.83 mg/dL versus YSI.
  • Percentage coefficients of variance were similar for SS (9.53%) and YSI (9.25%).
  • Limits of agreement were ± 5.7 mg/dL, with a high coefficient of individual agreement (0.995).

Conclusions:

  • StatStrip is a suitable replacement for YSI in pediatric hyperinsulinemic euglycemic clamp studies.
  • SS offers advantages: easier use, cost-effectiveness, speed, and reduced blood volume requirements.
  • Recommends considering StatStrip for future euglycemic clamp studies.
Abstract

More Related Videos

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat11:12

Hyperinsulinemic-Euglycemic Clamp in the Conscious Rat

Published on: February 7, 2011

54.0K
Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique07:35

Author Spotlight: Investigating the Blood Glucose Homeostasis in Murine Brain Using a Cost-Effective Hyperglycemic And Hypoglycemic Clamp Technique

Published on: January 26, 2024

2.1K

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Hyperglycemia01:29

Hyperglycemia

Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose...
25
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
1.3K
Hypoglycemia01:26

Hypoglycemia

Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
30
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
2.8K